Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1,094 MXN
Change Today +14.39 / 1.33%
Volume 575.0
BAX* On Other Exchanges
New York
SIX Swiss Ex
As of 4:09 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX*) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/24/15 - $1,094
52 Week Low
11/4/14 - $930.12
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

baxter international inc (BAX*) Related Businessweek News

View More BusinessWeek News

baxter international inc (BAX*) Details

Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products. The Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; and products and services related to pharmacy compounding, drug formulation and packaging technologies, as well as to treat renal disease, irreversible kidney failures, and other renal therapies. This segment also offers products for peritoneal dialysis, in-center and home hemodialysis, continuous renal replacement therapy, and other dialysis services. It markets its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and patients. The company operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. It has collaboration with Merrimack Pharmaceuticals, Inc. to develop and commercialize MM-398 injection; CTI BioPharma Corp. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products; and Onconova Therapeutics, Inc. for rigosertib anti-cancer compound. The company was founded in 1931 and is based in Deerfield, Illinois.

66,000 Employees
Last Reported Date: 02/26/15
Founded in 1931

baxter international inc (BAX*) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $755.0K
Corporate Vice President and President of Bio...
Total Annual Compensation: $833.8K
Corporate Vice President, General Counsel and...
Total Annual Compensation: $651.0K
Corporate Vice President of Human Resources
Total Annual Compensation: $525.3K
Compensation as of Fiscal Year 2014.

baxter international inc (BAX*) Key Developments

Baxter International Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Second Quarter 2015

Baxter International Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net sales $3,764 million compared to $3,848 million a year ago. a constant currency basis, sales increased 4%. Income from continuing operations before income taxes was $530 million compared to $653 million a year ago. Income from continuing operations was $420 million or $0.76 per diluted share compared to $507 million or $0.92 per diluted share a year ago. Net income was $430 million or $0.78 per diluted share compared to $556 million or $1.01 per diluted share a year ago. Adjusted pre-tax income from continuing operations (excluding special items) was $702 million compared to $765 million a year ago. Adjusted income from continuing operations (excluding special items) were $549 million or $1.00 per diluted share compared to $595 million or $1.09 per diluted share a year ago. Adjusted net income was $550 million or $1.00 per diluted share compared to $652 million or $1.19 per diluted share a year ago. GAAP earnings included net after-tax special items totaling $120 million or $0.22 per diluted share, primarily for intangible asset amortization and costs associated with the company's planned separation and the integration of its Gambro AB acquisition. These charges were partially offset by a benefit related to the reversal of certain business optimization reserves. The company provided earnings guidance for the second quarter 2015. The company expects sales growth of approximately 1%, excluding the impact of foreign currency. Including the impact of foreign currency, the company expects sales to decline approximately 9% to 10%. The company also expects earnings from continuing operations, before special items, of $0.92 to $0.96 per diluted share. The second quarter 2015 earnings guidance excludes approximately $0.08 per diluted share of projected intangible amortization expense. Reconciling for the inclusion of intangible asset amortization results in expected GAAP (Generally Accepted Accounting Principles) earnings of $0.84 to $0.88 per diluted share, before other special items, for the quarter. The company expects a tax rate of approximately 22% and an average share count of approximately 547 million shares.

Baxter International Inc. Presents Additional Data from the Phase III Clinical Trial of BAX 111

Baxter International Inc. presented additional data from the Phase III clinical trial of BAX 111, the first highly-purified recombinant von Willebrand Factor (rVWF) in clinical development as a treatment for patients with von Willebrand disease, the most common type of inherited bleeding disorder.1 The data were presented as an Abstract of Distinction during an oral session at the 2015 Scientific Symposium of the Hemostasis and Thrombosis Research Society (HTRS) in New Orleans, La. and expand on the topline data first disclosed in 2014. The trial met its primary efficacy endpoint defined by the number of patients who achieved treatment success for control of bleeding episodes. All patients treated in the full analysis set (N=22) experienced a 100% treatment success rating based on a 4-point efficacy rating scale, comparing estimated number of infusions needed to treat the bleeding episodes to the actual number of infusions administered. Efficacy for all treated bleeds (N=192) was rated excellent (96.9%) or good (3.1%), including major bleeds (6 excellent and 1 good). The median number of infusions required to treat bleeding events in the trial was 1 and the majority of events (81.8%) were resolved with a single infusion. The multi-center, open-label clinical trial was designed to assess the safety, efficacy and pharmacokinetics of BAX 111 among patients with severe von Willebrand disease aged 18 to 65 years. Bleeding events that occurred during the study were treated with rVWF (40-60 IU/kg; up to 80 IU/kg for major bleeds) initially together with rFVIII and subsequently alone if hemostatic FVIII levels were maintained. rVWF pharmacokinetic (PK) parameters were determined with and without rFVIII and repeated after 6 months for rVWF; these analyses found that rVWF PK was not affected by administration together with rFVIII. The recombinant technology used to produce BAX 111 avoids certain protein maturation processes that typically occur with plasma fractionation. This preserves large functional units known as ultra large multimers, which have been shown to be efficient in clot formation and FVIII stabilization.

Coherus BioSciences and Baxter International Amend CHS-0214 Collaboration Agreement

Coherus BioSciences and Baxter International have made amendments to certain financial terms of their collaboration agreement that was signed to develop and commercialise CHS-0214, an etanercept biosimilar product candidate, for Europe, Canada, Brazil, and certain other markets. Both firms signed the contract in August 2013. Under the amended contract, certain existing milestones and funding obligations have been revised, and the deal has been expanded to include select pre-commercialisation activities. The received milestone payments are likely to exceed the earlier Baxter funding obligations by around USD 12 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX*:MM $1,094.00 MXN +14.39

BAX* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,948 JPY -27.50
Kimberly-Clark Corp $111.64 USD -0.06
Mylan NV $76.06 USD +2.37
Stryker Corp $96.90 USD -0.28
Takeda Pharmaceutical Co Ltd ¥6,247 JPY -52.00
View Industry Companies

Industry Analysis


Industry Average

Valuation BAX* Industry Range
Price/Earnings 20.9x
Price/Sales 2.3x
Price/Book 4.8x
Price/Cash Flow 16.3x
TEV/Sales 1.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at